KRAS and pancreatic neoplasm: CDK8 expression was found increased in KRAS-mutated pancreatic cancer samples [162], while KRAS-mutated PDAC was shown to be sensitive to CDK9-inhibition in patient-derived xenografts [163], and downstream inhibition of KRAS via AKT-inhibition combined with CDK-inhibition via dinaciclib showed dramatic improvements—even complete responses—in patient-derived xenograft models of pancreatic cancer in mice [164].